N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

A Bundled Intervention to End Opioid Overdoses

Sponsor: University of Alabama at Birmingham • ClinicalTrials.gov ID: NCT07485335

Registry updated: 2026-10-02
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bundled intervention is proposed, including telehealth, peer support specialist, buprenorphine, and linkage for definitive care, that is designed to increase treatment uptake in this patient population post-ED discharge, reduce repeat opioid overdoses, and end overdose deaths.

Interventions

  • Bundled intervention (Experimental) (Other)
    a bundled intervention, including peer support, buprenorphine , telehealth, and linkage to community-based addiction programs.
  • control group (Other)
    participants will not be intervened with this bundled treatment, but continue the usual care that has been established at University of Alabama at Birmingham (UAB) hospital
  • Buprenorphine (Experimental) (Drug)
    Participants in the experimental arm will receive buprenorphine treatment for opioid use disorder, including buprenorphine/naloxone (sublingual film or tablet), buprenorphine (sublingual tablet), or buprenorphine extended-release, as determined by the study physician via telehealth. Medication will be provided for the duration of the 12-week intervention period. Participants without insurance or who are underinsured will be provided medication at no cost to ensure equitable access.
  • Scheduled Peer Support Specialist (Experimental) (Behavioral)
    Participants in the experimental arm will be introduced to a peer support specialist prior to hospital discharge. Peer support specialists, who have lived experience with substance use disorder and recovery, will provide ongoing support throughout the 12-week intervention period. Specialists will assist participants in navigating and attending community-based addiction treatment resources, including buprenorphine clinics and substance use treatment programs. At the conclusion of the 12-week intervention, participants will receive a warm handoff from the peer support specialist to facilitate linkage to long-term community-based addiction treatment and recovery resources.
  • Telemedicine Buprenorphine Treatment (Other)
    Participants in the experimental arm will receive telehealth-enabled services throughout the 12-week intervention period. Addiction physicians will conduct virtual visits to evaluate, prescribe, and manage buprenorphine for opioid use disorder. Peer support specialists will maintain scheduled contact with participants via telehealth to provide ongoing support and monitor participant progress. Follow-up assessments at 1 and 3 months will be completed remotely via survey links sent to participants' cell phones and/or emails through REDCap, with reminder messages sent twice daily for 5 days prior to each assessment.

Eligibility criteria

Inclusion Criteria: 1. discharged from the ED and inpatient settings at the UAB hospital 2. 19 years or older (the age of majority in Alabama); 3. diagnosis of OUD and experiencing opioid overdose in the last 12 months; 4. prescribed buprenorphine in the ED and willing to continue buprenorphine post-ED discharge; 5. English speaking; 6. not actively psychotic and suicidal, or cognitively impaired. 7. Patients who are admitted to the hospital from the ED will be eligible for enrollment. Exclusion Criteria: 1. living in a restricted environment (e.g., prison or jail facility, etc.); 2. currently enrolled in other clinical studies; 3. anticipated to take other prescribed opioids except buprenorphine for a medical condition longer than three months; 4. known allergic reaction to buprenorphine; 5. critically ill or injured; 6. females with pregnancy (they are anticipated to request a higher level of care). 7. living outside of Alabama

Conditions

Opioid Use Disorder Opioid Overdose

Locations

  • UAB — Birmingham, Alabama, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record